A phase 1b dose-escalation study of TRC105 (endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma (mRCC)

Authors
Category Primary study
ConferenceAnnals of Oncology
Year 2016
This article has no abstract
Epistemonikos ID: 4915940715d4d402aafedfa763b8edbb34d87eba
First added on: Dec 20, 2022